Hospira Announces A Nationwide Recall of Certain Lots of Injectable Carboplatin, Cytarabine, Paclitaxel and Methotrexate Due to Glass Vial Defect

by FDA on July 14, 2012

in FDA Recalls,Food Recalls

Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, issued this press release today to further inform the general public about a previously communicated user level recall of a total of 19 lots of carboplatin, cytarabine, paclitaxel, and methotrexate (see table below) in the United States due to visible particles embedded in the glass located at the neck of the vial. There may be potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

This is a summary of a recall issued by the Food and Drug Administration (FDA). The link below will take you to the original recall press release containing complete information, including instructions about what to do if you are affected by this recall.

View Full Details Of Original FDA Recall Notice Here.

Leave a Comment

Previous post:

Next post: